Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Central nervous system complications of immune checkpoint inhibitors: A comprehensive review.
Lopes S, Pabst L, Bahougne T, Barthélémy P, Guitton R, Didier K, Geoffrois L, Granel-Brocard F, Mennecier B, Mascaux C, Kremer S, Collongues N. Lopes S, et al. Among authors: collongues n. Crit Rev Oncol Hematol. 2024 Dec 12;206:104595. doi: 10.1016/j.critrevonc.2024.104595. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 39674302 Free article. Review.
MRI management of NMOSD and MOGAD: Proposals from the French Expert Group NOMADMUS.
Durand-Dubief F, Shor N, Audoin B, Bourre B, Cohen M, Kremer S, Maillart E, Papeix C, Ruet A, Savatovsky J, Tourdias T, Ayrignac X, Ciron J, Collongues N, Laplaud D, Michel L, Deschamps R, Thouvenot E, Zephir H, Marignier R, Cotton F; NOMADMUS Study Group. Durand-Dubief F, et al. Among authors: collongues n. J Neuroradiol. 2024 Dec 1;52(1):101235. doi: 10.1016/j.neurad.2024.101235. Online ahead of print. J Neuroradiol. 2024. PMID: 39626832 Free article.
Assessment of the concomitant action of XBD173 and interferon β in a mouse model of multiple sclerosis using infrared marker bands.
Sirinukunwattana K, Klein C, Clarke PFA, Marcou G, Meyer L, Collongues N, de Sèze J, Hellwig P, Patte-Mensah C, El Khoury Y, Mensah-Nyagan AG. Sirinukunwattana K, et al. Among authors: collongues n. Spectrochim Acta A Mol Biomol Spectrosc. 2025 Feb 15;327:125390. doi: 10.1016/j.saa.2024.125390. Epub 2024 Nov 3. Spectrochim Acta A Mol Biomol Spectrosc. 2025. PMID: 39515236 Free article.
Teriflunomide, cognition and MRI: A longitudinal study.
Pfaff L, Mondino M, Loeb Q, Noblet V, Berthe C, Kremer L, Bigaut K, Collongues N, De Seze J. Pfaff L, et al. Among authors: collongues n. Mult Scler Relat Disord. 2024 Oct;90:105793. doi: 10.1016/j.msard.2024.105793. Epub 2024 Jul 31. Mult Scler Relat Disord. 2024. PMID: 39197351
Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study.
Deschamps R, Guillaume J, Ciron J, Audoin B, Ruet A, Maillart E, Pique J, Benyahya L, Laplaud DA, Michel L, Collongues N, Cohen M, Ayrignac X, Thouvenot E, Zephir H, Bourre B, Froment Tilikete C, Moreau T, Cantagrel P, Kerschen P, Cabasson S, Maubeuge N, Hankiewicz K, Nifle C, Berger E, Megherbi H, Magy L, Klapczynski F, Sarov Riviere M, Giannesini C, Hamelin L, Giroux M, Branger P, Maurousset A, Mathey G, Moulin M, Mélé N, Papeix C, Marignier R; as the NOMADMUS study group. Deschamps R, et al. Among authors: collongues n. Neurology. 2024 Aug 13;103(3):e209624. doi: 10.1212/WNL.0000000000209624. Epub 2024 Jul 11. Neurology. 2024. PMID: 38991174
Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations.
Deschamps R, Papeix C, Ayrignac X, Bourre B, Ciron J, Cohen M, Collongues N, Deiva K, Durand Dubief F, Laplaud DA, Maillart E, Michel L, Pique J, Ruet A, Thouvenot E, Zéphir H, Marignier R, Audoin B. Deschamps R, et al. Among authors: collongues n. Rev Neurol (Paris). 2024 Oct;180(8):711-714. doi: 10.1016/j.neurol.2024.06.003. Epub 2024 Jul 4. Rev Neurol (Paris). 2024. PMID: 38969609 No abstract available.
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.
Gavoille A, Rollot F, Casey R, Kerbrat A, Le Page E, Bigaut K, Mathey G, Michel L, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Manchon E, Lapergue B, Wiertlewski S, De Sèze J, Vukusic S, Laplaud DA; OFSEP Investigators. Gavoille A, et al. JAMA Neurol. 2024 Aug 1;81(8):814-823. doi: 10.1001/jamaneurol.2024.1961. JAMA Neurol. 2024. PMID: 38949816
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. Jouvenot G, et al. Among authors: collongues n. JAMA Neurol. 2024 May 1;81(5):490-498. doi: 10.1001/jamaneurol.2024.0395. JAMA Neurol. 2024. PMID: 38526462
155 results